Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2
Chrysovalantis Voutouri, C. Corey Hardin, Vivek Naranbhai, Mohammad R. Nikmaneshi, Melin J. Khandekar, Justin F Gainor, Triantafyllos Stylianopoulos, Lance L. Munn, Rakesh K. Jain
doi: https://doi.org/10.1101/2022.06.30.22277076
Chrysovalantis Voutouri
aEdwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
bCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering,University of Cyprus, Nicosia, Cyprus
C. Corey Hardin
cDepartment of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Vivek Naranbhai
dMassachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA
eDana-Farber Cancer Institute, Boston, MA
fCenter for the AIDS Programme of Research in South Africa, Durban, South Africa
Mohammad R. Nikmaneshi
aEdwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
gDepartment of Mechanical Engineering, Sharif University of Technology, Tehran, Iran
Melin J. Khandekar
hDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Justin F Gainor
dMassachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Triantafyllos Stylianopoulos
bCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering,University of Cyprus, Nicosia, Cyprus
Lance L. Munn
aEdwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Rakesh K. Jain
aEdwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Data Availability
Data availability. All data supporting the findings of this study are available in the paper and the Supplementary Information. Code availability. The COMSOL code will become available in Zenodo upon acceptance of the manuscript.
Posted July 03, 2022.
Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2
Chrysovalantis Voutouri, C. Corey Hardin, Vivek Naranbhai, Mohammad R. Nikmaneshi, Melin J. Khandekar, Justin F Gainor, Triantafyllos Stylianopoulos, Lance L. Munn, Rakesh K. Jain
medRxiv 2022.06.30.22277076; doi: https://doi.org/10.1101/2022.06.30.22277076
Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2
Chrysovalantis Voutouri, C. Corey Hardin, Vivek Naranbhai, Mohammad R. Nikmaneshi, Melin J. Khandekar, Justin F Gainor, Triantafyllos Stylianopoulos, Lance L. Munn, Rakesh K. Jain
medRxiv 2022.06.30.22277076; doi: https://doi.org/10.1101/2022.06.30.22277076
Subject Area
Subject Areas
- Addiction Medicine (390)
- Allergy and Immunology (705)
- Anesthesia (196)
- Cardiovascular Medicine (2877)
- Dermatology (245)
- Emergency Medicine (432)
- Epidemiology (12603)
- Forensic Medicine (10)
- Gastroenterology (811)
- Genetic and Genomic Medicine (4476)
- Geriatric Medicine (407)
- Health Economics (717)
- Health Informatics (2867)
- Health Policy (1057)
- Hematology (378)
- HIV/AIDS (907)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (465)
- Neurology (4233)
- Nursing (226)
- Nutrition (619)
- Oncology (2218)
- Ophthalmology (630)
- Orthopedics (255)
- Otolaryngology (322)
- Pain Medicine (270)
- Palliative Medicine (83)
- Pathology (489)
- Pediatrics (1182)
- Primary Care Research (485)
- Public and Global Health (6818)
- Radiology and Imaging (1502)
- Respiratory Medicine (907)
- Rheumatology (430)
- Sports Medicine (373)
- Surgery (475)
- Toxicology (59)
- Transplantation (204)
- Urology (175)